<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505410</url>
  </required_header>
  <id_info>
    <org_study_id>20200436</org_study_id>
    <nct_id>NCT04505410</nct_id>
  </id_info>
  <brief_title>Xeljanz and Healthy Diet</brief_title>
  <official_title>A Randomized Control Study to Examine the Influence of a Healthy Diet on Moderate to Severe Ulcerative Colitis Patients Undergoing Tofacitinib (Xeljanz) Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a diet intervention (the Fasting Mimicking&#xD;
      diet) will help induce clinical and biochemical response to tofacitinib therapy in patients&#xD;
      with ulcerative colitis. Study period will be 8 weeks during induction of tofacitinib. The&#xD;
      primary aims of this study are to determine clinical response and improvement in fecal&#xD;
      calprotectin and C-reactive protein levels. Secondary outcomes will include assessment of&#xD;
      changes in the stool microbiome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who achieved clinical response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical response will be evaluated using the Simple Clinical Colitis Activity Index (SCCAI). The SCCAI has a total range from 0-19 with a higher score indicating greater disease activity. A clinical response is defined as a SCCAI decrease of â‰¥2 points from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fecal Calprotectin levels</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Calprotectin levels will be evaluated using fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP levels</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>C-Reactive Protein (CRP) levels will be evaluated using blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Tofacitinib plus FMD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tofacitinib only group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>10mg tofacitinib tablets taken twice daily for eight weeks</description>
    <arm_group_label>Tofacitinib only group</arm_group_label>
    <arm_group_label>Tofacitinib plus FMD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fast Mimicking Diet</intervention_name>
    <description>FMD is a five day meal plan that includes foods such as soups, snacks, bards, teas and supplements (omega-3 fatty acids) for a total of 66 items per box. The diet is plant-based, gluten free and dairy free without any artificial preservatives, chemicals or biologically active ingredients.</description>
    <arm_group_label>Tofacitinib plus FMD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with ulcerative colitis who are beginning tofacitinib therapy.&#xD;
&#xD;
          2. Patients aged 18 years or older.&#xD;
&#xD;
          3. Patients with active disease defined as simple clinical colitis activity index (SCCAI)&#xD;
             &gt;2&#xD;
&#xD;
          4. Patients who have not been on antibiotics for 2 weeks or probiotics.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 18 years.&#xD;
&#xD;
          2. Patients that do not meet the inclusion criteria specified above.&#xD;
&#xD;
          3. Patients with clinical signs of fulminant colitis, toxic megacolon, ischemic colitis&#xD;
             or impending hospitalization for severe ulcerative colitis.&#xD;
&#xD;
          4. Patients with concomitant infectious colitis.&#xD;
&#xD;
          5. Patients allergic nuts/soy/sesame/oats.&#xD;
&#xD;
          6. Patients who do not like the food items that form part of the kits for the fasting&#xD;
             mimicking diet (see below).&#xD;
&#xD;
          7. Patients that are diabetics on a glucose lowering drug.&#xD;
&#xD;
          8. Individuals with a history of syncope/presyncope with fasting or from medical&#xD;
             conditions.&#xD;
&#xD;
          9. Women who are pregnant or nursing.&#xD;
&#xD;
         10. Individuals with very low BMI&lt; or equal to 18.&#xD;
&#xD;
         11. Patients with the following comorbidities: chronic kidney disease, diabetes, active&#xD;
             cancer.&#xD;
&#xD;
         12. Prohibited concomitant therapies will include TNF antagonists, azathioprine,&#xD;
             methotrexate, and mercaptopurine.&#xD;
&#xD;
         13. Patients who routinely have fasting eating habits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oriana Damas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grechen Mills, BS</last_name>
    <phone>305-243-6405</phone>
    <email>gmills@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grechen Mills, BS</last_name>
      <phone>305-243-6405</phone>
      <email>gmills@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Oriana Damas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastro Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grechen Mills, BS</last_name>
      <phone>305-243-6405</phone>
      <email>gmills@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Oriana Damas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Oriana Mazorra Damas</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

